News

The National Institutes of Health has released data from the first 4500 patients in the ABCD study.

Makena remains the first and only FDA-approved treatment option currently available for pregnant women who had a prior spontaneous preterm birth.

The PDUFA date has been set for June 20. In a previous trial of 22 patients, those on the Shire product reported a mean of 6.1 attacks compared with 12.7 with placebo

A study comparing cognitive endophenotypes to see which mediate genetic risk of ADHD found working memory and arousal regulation (vigilance) to be the top 2 candidates.

Following decades of research prohibition, physicians are once again raising the psilocybin question. This time, they’re letting data define the answer.

In a first-of-its-kind study, researchers reprogrammed cells to shut down pain receptors when the patient is exposed to the scent of spearmint.

The findings indicate that the test can reliably predict the absence of intracranial lesions.

The 5 novel loci identified associated with ADHD provide evidence for a shared genetic basis between ADHD and educational attainment.

Late last night, U.S. FDA Commissioner Scott Gottlieb released a statement regarding the Administration’s request for new FDA funding to “promote innovation and broaden patient access through competition.”

A researcher at the Feinstein Institute for Medical Research has been awarded two grants for clinical trials on existing FDA-approved drugs that can be indicated to treat hereditary hemorrhagic telangiectasia.

Genentech announced that its Supplemental Biologics License Application was accepted, and the FDA granted Priority Review for the use of rituximab for the treatment of pemphigus vulgaris.

The guidelines were created by Vanderbilt’s Asthma Steering Committee and implemented in May 2014.

On February 27, Marquette University’s College of Health Sciences will host a discussion led by Harmony 4 Hope and other rare disease advocates in honor of rare disease day.

Data published in The Orphanet Journal of Rare Diseases confirmed that currently-available enzyme replacement therapies are unable to reverse or stabilize the progression of Pompe disease.

In a phase 3 trial, 89% of those assigned to rituximab plus short-term prednisone were completely in remission and off therapy in 24 months.

Former flaws in medical care may have driven the generation's rate of infection, but modern testing will improve it.

Study results suggest that estrogen and progesterone exert a significant effect on HIV replication.

The study highlights potential racial and medical characteristics that affect the access of the patients to FMT.

Vertex's tezacafor/ivacaftor and ivacaftor is the company's third combination treatment approved for cystic fibrosis.

Imara has announced that it has dosed the first patient in its Phase 2a clinical trial of IMR-687 in adult patients with sickle cell disease.

Catabasis Pharmaceuticals reported positive safety and efficacy results, displaying the preservation of muscle function and sustained disease-modifying effects in Duchenne muscular dystrophy with edasalonexent.

Spontaneous clearance peaks at 12 months, with 36.1% of patients achieving spontaneous clearance of HCV by that point in time.

The Sandoz therapy now has received an indication for use in either 40 mg/mL or 20 mg/mL doses, with the lower quantity having been granted approval in June 2015.

The U.S. FDA approved tezacaftor/ivacaftor and ivacaftor (Symdeko) for the treatment of the underlying cause of cystic fibrosis in people ages 12 years and older who have 2 copies of the F508del mutation.

There is some evidence that taking branched chain neutral amino acids may help TD.

Computerized low luminance visual acuity and low luminance deficit in patients with early/intermediate age-related macular degeneration were linked to LLQ scores.

Buprenorphine induction was associated with a 19.3% reduction in total outpatient costs, as well as better treatment adherence.

Phenobarbital’s reputation among physicians and patients is aided by its history — its century-plus usage as an anticonvulsant lends to the notion that it’s a safer option. It may not be.

The novel solution is being investigated for patient acceptability and compliance to bowel cleansing.

Audentes Therapeutics has initiated the first patient dosing of VALENS, a Phase 1/2 clinical trial of a potential treatment for Crigler-Najjar syndrome called AT342.